呼吸道感染、耳鼻喉感染、泌尿系感染、皮肤和软组织感染、败血症、脑膜炎、淋病、骨和关节感染及 产褥期和妇科感染，最早由GSK公司研发，于1978在英国、意大利等国家上市。IQVIA数据库显示， 2024年中国大陆医院采购头孢呋辛钠注射剂金额为人民币26.2亿元。 注射用氨曲南适用于治疗敏感革兰氏阴性菌引起的感染：尿路（复杂和单纯 的）、下呼吸道感染、败 血症、皮肤和皮肤结构感染、腹腔内感染和妇科感染， 由BMS公司研发，最早于1984年在意大利上 市。IQVIA 数据库显示，2024年中国大陆医院采购氨曲南注射剂金额为人民币1.63亿元。 近日，上海医药发布公告称，公司下属上海上药新亚药业有限公司的注射用头孢呋辛钠、注射用氨曲南 收到国家药品监督管理局颁发的《药品补充申请批准通知书》，前述药品通过仿制药质量和疗效一致性 评价。 (编辑：杨燕 林辰)关键字： 医疗 公告显示，注射用头孢呋辛钠适用于治疗以下疾病中特定微生物敏感菌株引起的感染： （上海医药公告） ...

Group 1: Company Announcements - ChaoYing Electronics' wholly-owned subsidiary plans to invest 1.468 billion RMB in an AI computing high-end printed circuit board expansion project in Thailand, aiming to enhance its product layout in high-end PCB applications such as routers and AI servers [1] - DeMingLi is in the process of planning a refinancing matter, which is still in the internal communication stage without a clear plan or determined financing amount [1] - *ST YuanCheng's stock has triggered mandatory delisting due to a market capitalization below 500 million RMB for 20 consecutive trading days, leading to a suspension of trading starting November 11, 2025 [1] Group 2: Investment and Cooperation - ZhongBei Communication signed a framework agreement for comprehensive computing services worth 1 billion RMB with Hongxin Electronics, with a service period of 60 months [2] - ShangTai Technology plans to invest approximately 4.07 billion RMB in a project to produce 200,000 tons of lithium-ion battery anode materials in Shanxi Province [3] Group 3: Clinical Trials and Approvals - Maiwei Bio's innovative drug 9MW3811 injection for pathological scars has received approval for a Phase II clinical trial, with plans to start by the end of 2025, positioning it as the first IL-11 targeted drug in this indication [3]

北京商报讯（记者 王寅浩 宋雨盈）11月10日，上海医药发布公告称，公司下属上海上药新亚药业有限 公司收到国家药品监督管理局颁发的《药品补充申请批准通知书》，注射用头孢呋辛钠、注射用氨曲南 通过仿制药质量和疗效一致性评价。 公告显示，注射用头孢呋辛钠适用于治疗呼吸道感染、耳鼻喉感染、泌尿系感染等疾病中特定微生物敏 感菌株引起的感染，最早于1978在英国、意大利等国家上市；注射用氨曲南适用于治疗尿路（复杂和单 纯的）、下呼吸道感染等敏感革兰氏阴性菌引起的感染，最早于1984年在意大利上市。 ...

Core Insights - Shanghai Pharmaceuticals' subsidiary, Shanghai Shenyang Pharmaceutical Co., has received approval from the National Medical Products Administration for its injectable drugs, Cefuroxime Sodium and Aztreonam, which have passed the consistency evaluation for generic drug quality and efficacy [1][2] Group 1: Cefuroxime Sodium - Cefuroxime Sodium is indicated for infections caused by specific sensitive strains of microorganisms, including respiratory, ENT, urinary, skin, and soft tissue infections, among others [1] - The drug was originally developed by GSK and launched in the UK and Italy in 1978 [1] - As of the announcement date, the company has invested approximately RMB 3.5343 million in the research and development of this drug [1] - The total procurement amount for Cefuroxime Sodium injection in mainland China hospitals in 2024 is projected to be RMB 2,621.73 million [1] Group 2: Aztreonam - Aztreonam is used to treat infections caused by sensitive Gram-negative bacteria, including urinary tract infections, lower respiratory tract infections, and skin infections [2] - The drug was developed by BMS and first launched in Italy in 1984 [2] - The company has invested approximately RMB 6.6794 million in the research and development of Aztreonam [2] - The total procurement amount for Aztreonam injection in mainland China hospitals in 2024 is projected to be RMB 162.7 million [2]

（编辑 楚丽君） 证券日报网讯 11月10日晚间，上海医药发布公告称，近日，公司下属上海上药新亚药业有限公司的注 射用头孢呋辛钠、注射用氨曲南收到国家药品监督管理局颁发的《药品补充申请批准通知书》（通知书 编号：2025B05069、2025B05110、2025B05111），前述药品通过仿制药质量和疗效一致性评价。 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shenyang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for its injectable drugs, Cefuroxime Sodium and Aztreonam, which passed the consistency evaluation of generic drug quality and efficacy [1] Group 1: Drug Approvals - The injectable Cefuroxime Sodium is indicated for infections caused by specific sensitive strains of microorganisms, including respiratory infections, ENT infections, urinary tract infections, skin and soft tissue infections, sepsis, meningitis, gonorrhea, bone and joint infections, as well as postpartum and gynecological infections [1] - The injectable Aztreonam is indicated for infections caused by sensitive Gram-negative bacteria, including urinary tract infections (both complicated and uncomplicated), lower respiratory tract infections, sepsis, skin and skin structure infections, intra-abdominal infections, and gynecological infections [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyu New Asia Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for its injectable drugs, Cefuroxime Sodium and Aztreonam, which passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1: Product Approvals - The injectable Cefuroxime Sodium is indicated for treating infections caused by specific sensitive strains of microorganisms, including respiratory infections, ENT infections, urinary tract infections, skin and soft tissue infections, sepsis, meningitis, gonorrhea, bone and joint infections, as well as postpartum and gynecological infections [1] - Cefuroxime Sodium was originally developed by GSK and was first launched in countries like the UK and Italy in 1978 [1] - The injectable Aztreonam is indicated for infections caused by sensitive Gram-negative bacteria, including urinary tract infections (both complicated and uncomplicated), lower respiratory tract infections, sepsis, skin and skin structure infections, intra-abdominal infections, and gynecological infections [1] - Aztreonam was developed by BMS and was first launched in Italy in 1984 [1]